Logo image of PACB

PACIFIC BIOSCIENCES OF CALIF (PACB) Stock Price, Quote, News and Overview

NASDAQ:PACB - Nasdaq - US69404D1081 - Common Stock - Currency: USD

1.69  +0.04 (+2.42%)

After market: 1.6992 +0.01 (+0.54%)

PACB Quote, Performance and Key Statistics

PACIFIC BIOSCIENCES OF CALIF

NASDAQ:PACB (1/24/2025, 4:04:58 PM)

After market: 1.6992 +0.01 (+0.54%)

1.69

+0.04 (+2.42%)

Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryLife Sciences Tools & Services
Statistics
52 Week High7.4
52 Week Low1.16
Market Cap462.82M
Shares273.86M
Float248.25M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)02-13 2025-02-13/amc
IPO10-27 2010-10-27


PACB short term performance overview.The bars show the price performance of PACB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

PACB long term performance overview.The bars show the price performance of PACB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PACB is 1.69 USD. In the past month the price decreased by -16.24%. In the past year, price decreased by -76.5%.

PACIFIC BIOSCIENCES OF CALIF / PACB Daily stock chart

PACB Latest News, Press Releases and Analysis

News Image
a day ago - PacBio

PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider

MENLO PARK, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions,...

News Image
10 days ago - PacBio

PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions,...

News Image
10 days ago - PacBio

PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

Commenced shipment of the Vegaâ„¢ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the...

News Image
14 days ago - PacBio

PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus...

PACB Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 26.82 219.87B
DHR DANAHER CORP 33.04 177.54B
A AGILENT TECHNOLOGIES INC 28.63 43.19B
IQV IQVIA HOLDINGS INC 18.81 37.09B
MTD METTLER-TOLEDO INTERNATIONAL 34.89 28.09B
WST WEST PHARMACEUTICAL SERVICES 51.04 24.98B
WAT WATERS CORP 36.11 24.42B
ILMN ILLUMINA INC 78.74 21.60B
ICLR ICON PLC 14.29 16.55B
AVTR AVANTOR INC 22.51 15.01B
RVTY REVVITY INC 26.04 14.99B
TECH BIO-TECHNE CORP 43.04 12.24B

About PACB

Company Profile

PACB logo image Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 796 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Company Info

PACIFIC BIOSCIENCES OF CALIF

1305 O'brien Drive

Menlo Park CALIFORNIA 94025 US

CEO: Christian O. Henry

Employees: 796

Company Website: https://www.pacb.com/

Investor Relations: https://investor.pacificbiosciences.com

Phone: 16505218000

PACB FAQ

What is the stock price of PACB?

The current stock price of PACB is 1.69 USD.


What is the symbol for PACIFIC BIOSCIENCES OF CALIF stock?

The exchange symbol of PACIFIC BIOSCIENCES OF CALIF is PACB and it is listed on the Nasdaq exchange.


On which exchange is PACB stock listed?

PACB stock is listed on the Nasdaq exchange.


Is PACB a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PACB, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PACB.


Does PACB stock pay dividends?

PACB does not pay a dividend.


When does PACB stock report earnings?

PACB will report earnings on 2025-02-13, after the market close.


What is the Price/Earnings (PE) ratio of PACB?

PACB does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.46).


What is the Short Interest ratio of PACB stock?

The outstanding short interest for PACB is 22.9% of its float.


PACB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PACB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PACB. Both the profitability and financial health of PACB have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PACB Financial Highlights

Over the last trailing twelve months PACB reported a non-GAAP Earnings per Share(EPS) of -1.46. The EPS decreased by -14.96% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -27.19%
ROE -87.01%
Debt/Equity 1.97
Chartmill High Growth Momentum
EPS Q2Q%15.38%
Sales Q2Q%-28.23%
EPS 1Y (TTM)-14.96%
Revenue 1Y (TTM)2.15%

PACB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to PACB. The Buy consensus is the average rating of analysts ratings from 22 analysts.

For the next year, analysts expect an EPS growth of -9.17% and a revenue growth -21.98% for PACB


Ownership
Inst Owners85.81%
Ins Owners0.59%
Short Float %22.9%
Short Ratio5.47
Analysts
Analysts75.45
Price Target2.92 (72.78%)
EPS Next Y-9.17%
Revenue Next Year-21.98%